News | Radiology Business | July 03, 2024

A new Harvey L. Neiman Health Policy Institute (HPI) study found that radiologists interpreted 72.1% of all imaging studies for Medicare fee-for-service beneficiaries in 2022, with the remaining 27.9% performed by other types of clinicians.

A new Harvey L. Neiman Health Policy Institute (HPI) study found that radiologists interpreted 72.1% of all imaging studies for Medicare fee-for-service beneficiaries in 2022, with the remaining 27.9% performed by other types of clinicians.

A new Harvey L. Neiman Health Policy Institute (HPI) study found that radiologists interpreted 72.1% of all imaging studies for Medicare fee-for-service beneficiaries in 2022, with the remaining 27.9% performed by other types of clinicians. Image courtesy: Getty Images


July 3, 2024 — A new Harvey L. Neiman Health Policy Institute (HPI) study found that radiologists interpreted 72.1% of all imaging studies for Medicare fee-for-service beneficiaries in 2022, with the remaining 27.9% performed by other types of clinicians. According to a written study summary released by HPI, market share varied by imaging modality; radiologists interpreted 97.3% of computed tomography (CT), 91.0% of magnetic resonance (MR), 76.6% of radiology/fluoroscopy (XR), 50.9% of nuclear medicine (NM), and 33.9% of ultrasound. The research, published June 28 in the Journal of the American College of Radiology, JACR, was based on 123 million Medicare Part B imaging claims in 2022. Additional study findings and highlights are shared below.

For non-cardiac imaging, the study found that radiologists interpreted nearly all imaging in the hospital outpatient, inpatient, and emergency department settings: 99.5% for CT; 99.4% for MR; 98.9% for NM; 97.9% for XR; and 79.3% for ultrasound. Even in the office setting, radiologists interpreted a majority of non-cardiac advanced imaging (84.4% of CT, 78.7% of MR, 85.4% of NM) but a minority of XR (43.1%) and ultrasound (29.2%), according to the study overview.

“There are economic benefits to non-radiologists that likely contribute to their majority market share of XR and ultrasound imaging. These providers have financial incentives for self-referral of imaging,” stated Eric Christensen, PhD, Research Director at the Neiman Institute. Christensen continued, “The Stark Law, which was designed in part to prohibit self-referral of imaging to facilities in which the referring physician had a financial interest, have largely been ineffective. The literature shows that even after the passage of the Stark Law, self-referring non-radiologists ordered 1.2 to 6.4 times more imaging studies than those who do not self-refer.”

“Non-radiologists have likely been more successful with capturing market share with XR and ultrasound than with advanced modalities because imaging volume from their practice’s patients alone may be sufficient for a positive return on investment for providing these services” stated coauthor Jeffrey Newhouse, MD, Professor Emeritus of CUIMC Department of Radiology, Columbia University Medical Center. “However, advanced imaging involves substantially higher capital and operational costs, making the economics impractical for most practices,” Newhouse added.

The study found that radiologist market share also varied by the focus body region, and in particular for cardiac imaging. For non-cardiac imaging, radiologists interpreted 97.6% of CT, 91.4% of MR, 95.6% of NM, 76.6% of XR, and 53.0% of ultrasound. In contrast, radiologists’ share of cardiac imaging was 67.6% of CT, 42.2% of MR, 11.8% of NM, and 0.4% of ultrasound.

“Cardiologists interpret most cardiac imaging, and a greater share than radiologists for all modalities except cardiac CT” stated Christensen, adding, “Cardiology is the only non-radiology specialty that interprets a large percentage of advanced imaging — CT, MR, and NM — but only cardiac imaging.”

The Harvey L. Neiman Health Policy Institute, based in Reston, VA, is one of the nation’s leading medical imaging socioeconomic research organizations, which studies the role and value of radiology and radiologists in evolving health care delivery and payment systems and the impact of medical imaging on the cost, quality, safety and efficiency of health care.

Persons interested in obtaining a copy of the study can contact Nichole Gonzalez at ngonzalez@neimanhpi.org.

More information: www.neimanhpi.org


Related Content

News | Endoscopes

Oct. 22, 2025 — Fujifilm Healthcare Americas Corp. has launched its advanced endoscopy platform, the ELUXEO 8000 ...

Time October 23, 2025
arrow
News | X-Ray

Oct. 22, 2025 — Imaging technology company Adaptix has begun live imaging trials as part of a research program at the ...

Time October 22, 2025
arrow
News | Contrast Media

Oct. 21, 2025 — Subtle Medical, Inc., a provider of AI-powered medical imaging solutions, has announced positive ...

Time October 21, 2025
arrow
News | Artificial Intelligence

Oct. 20, 2025 — Viz.ai has launched of Viz Assist, a suite of autonomous AI agents that significantly enhance how care ...

Time October 20, 2025
arrow
News | Point-of-Care Ultrasound (POCUS)

Oct. 15, 2025 — GE HealthCare has announced the latest advancement in its Venue family of point-of-care ultrasound ...

Time October 16, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

September 24, 2025—According to the American Journal of Roentgenology (AJR), MRI can reliably identify lateral meniscal ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Oct. 01, 2025 – Nuclidium AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time October 02, 2025
arrow
News | Radiology Business | Harvey L. Neiman Health Policy Institute

Sept. 30, 2025 — A new study from the Harvey L. Neiman Health Policy Institute found that attrition (i.e., exit) from ...

Time October 02, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Sept. 10, 2025 —GE HealthCare announced it has entered into an agreement to acquire icometrix, a company focused on ...

Time September 10, 2025
arrow
News | Lung Imaging

Sept. 4, 2025 — Sentec recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance ...

Time September 08, 2025
arrow
Subscribe Now